Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
The purpose of this study is to assess the safety and efficacy of Gemcitabine/cisplatin combined with Adebrelimab and Mecapegfilgrastim in neoadjuvant treatment of potentially resectable Biliary Tract Neoplasms.
Biliary Tract Neoplasms
DRUG: Total Neoadjuvant Treatment
Objective response rate (ORR), ORR is defined as patients achieving clinical complete response (CR) or partial response (PR) according to RECIST v1.1, 18 weeks
overall survival (OS), Overall survival, 2 years
Progression free survival (PFS), PFS is defined as time interval from recruitment to tumor progression or censoring, 2 years|Pathological Complete Response Rate (pCR), pathological complete response rate, 18 weeks|Major Pathological Response Rate (MPR), MPR rate was defined as the percentage of patients who achieved a major pathological response (residual tumor â‰¤10%), 18 weeks
After being informed about the study and potential risks, patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be receive Gemcitabine/cisplatin combined with Adebrelimab and Mecapegfilgrastim three weeks a cycle, surgery was performed after 4 cycles.